丙型肝炎合并弥漫大B细胞淋巴瘤1例报告

涂芷馨; 黄剑洁; 王妍; 马博; 韩雨金; 郭亮; 温晓玉; 金清龙

doi:10.3969/j.issn.1001-5256.2022.10.024

丙型肝炎合并弥漫大B细胞淋巴瘤1例报告

DOI: 10.3969/j.issn.1001-5256.2022.10.024

吉林大学第一医院肝病科，长春 130021

基金项目:

国家自然科学基金 (81270484)

伦理学声明：本例报告已获得患者知情同意。

利益冲突声明：所有作者均声明不存在利益冲突。

作者贡献声明：涂芷馨、温晓玉、金清龙负责课题设计，资料分析，撰写论文；涂芷馨、郭亮参与收集数据，修改论文；黄剑洁、王妍、马博、韩雨金负责拟定写作思路，指导撰写文章并最后定稿。

详细信息

通信作者:
金清龙，jinql@jlu.edu.cn

计量
- 文章访问数: 260
- HTML全文浏览量: 74
- PDF下载量: 39
- 被引次数: 0
出版历程
- 收稿日期: 2022-03-14
- 录用日期: 2022-05-09
- 出版日期: 2022-10-20

Hepatitis C combined with diffuse large B-cell lymphoma: A case report

Department of Hepatology, The First Hospital of Jilin University, Changchun 130021, China

Research funding:

National Natural Science Foundation of China (81270484)

More Information

Corresponding author: JIN Qinglong, jinql@jlu.edu.cn(ORCID: 0000-0002-4626-9828)

摘要

- 丙型肝炎 /
- 淋巴瘤, 大B细胞, 弥漫性 /
- 治疗学
- Hepatitis C /
- Lymphoma, Large B-Cell, Diffuse /
- Therapeutics

HTML全文

图 1 淋巴结病理结果

注：a，肿瘤细胞异型性明显，核分裂易见，可见明显的核仁(HE染色，×200)；b，较多的核分裂可见淡染核仁居中的免疫母细胞(HE染色，×400)；c，Ki-67阳性(免疫组化，×200)；d，CD20阳性(免疫组化，×200)。

Figure 1. Pathological results of lymph node puncture

下载: 全尺寸图片幻灯片

参考文献(19)

[1]	GILL K, GHAZINIAN H, MANCH R, et al. Hepatitis C virus as a systemic disease: reaching beyond the liver[J]. Hepatol Int, 2016, 10(3): 415-423. DOI: 10.1007/s12072-015-9684-3.
[2]	POZZATO G, MAZZARO C, DAL MASO L, et al. Hepatitis C virus and non-Hodgkin's lymphomas: Meta-analysis of epidemiology data and therapy options[J]. World J Hepatol, 2016, 8(2): 107-116. DOI: 10.4254/wjh.v8.i2.107.
[3]	de SANJOSE S, BENAVENTE Y, VAJDIC CM, et al. Hepatitis C and non-Hodgkin lymphoma among 4784 cases and 6269 controls from the International Lymphoma Epidemiology Consortium[J]. Clin Gastroenterol Hepatol, 2008, 6(4): 451-458. DOI: 10.1016/j.cgh.2008.02.011.
[4]	GISBERT JP, GARCÍA-BUEY L, ARRANZ R, et al. The prevalence of hepatitis C virus infection in patients with non-Hodgkin's lymphoma[J]. Eur J Gastroenterol Hepatol, 2004, 16(2): 135-138. DOI: 10.1097/00042737-200402000-00003.
[5]	PETRUZZIELLO A, MARIGLIANO S, LOQUERCIO G, et al. Global epidemiology of hepatitis C virus infection: An up-date of the distribution and circulation of hepatitis C virus genotypes[J]. World J Gastroenterol, 2016, 22(34): 7824-7840. DOI: 10.3748/wjg.v22.i34.7824.
[6]	CHENG Z, ZHOU B, SHI X, et al. Extrahepatic manifestations of chronic hepatitis C virus infection: 297 cases from a tertiary medical center in Beijing, China[J]. Chin Med J (Engl), 2014, 127(7): 1206-1210.
[7]	TASLEEM S, SOOD GK. Hepatitis C associated B-cell non-hodgkin lymphoma: clinical features and the role of antiviral therapy[J]. J Clin Transl Hepatol, 2015, 3(2): 134-139. DOI: 10.14218/JCTH.2015.00011.
[8]	ZUCCA E, BERTONI F, VANNATA B, et al. Emerging role of infectious etiologies in the pathogenesis of marginal zone B-cell lymphomas[J]. Clin Cancer Res, 2014, 20(20): 5207-5216. DOI: 10.1158/1078-0432.CCR-14-0496.
[9]	SULYOK M, MAKARA M, U'JHELYI E, et al. Non-Hodgkin lymphoma and hepatitis C: where we are and what next?[J]. Pathol Oncol Res, 2015, 21(1): 1-7. DOI: 10.1007/s12253-014-9845-z.
[10]	VISCO C, FINOTTO S. Hepatitis C virus and diffuse large B-cell lymphoma: Pathogenesis, behavior and treatment[J]. World J Gastroenterol, 2014, 20(32): 11054-11061. DOI: 10.3748/wjg.v20.i32.11054.
[11]	COURONNÉ L, BACHY E, ROULLAND S, et al. From hepatitis C virus infection to B-cell lymphoma[J]. Ann Oncol, 2018, 29(1): 92-100. DOI: 10.1093/annonc/mdx635.
[12]	PAYDAS S, KILIC B, YAVUZ S, et al. Anti-HCV and HCV-RNA prevalence and clinical correlations in cases with non-Hodgkin's lymphoma[J]. Am J Hematol, 2003, 74(2): 89-93. DOI: 10.1002/ajh.10386.
[13]	VANNATA B, ARCAINI L, ZUCCA E. Hepatitis C virus-associated B-cell non-Hodgkin's lymphomas: what do we know?[J]. Ther Adv Hematol, 2016, 7(2): 94-107. DOI: 10.1177/2040620715623924.
[14]	SAKAI H, MIWA T, IKOMA Y, et al. Development of diffuse large B-cell lymphoma after sofosbuvir-ledipasvir treatment for chronic hepatitis C: A case report and literature review[J]. Mol Clin Oncol, 2020, 13(3): 1. DOI: 10.3892/mco.2020.2071.
[15]	POL S, VALLET-PICHARD A, HERMINE O. Extrahepatic cancers and chronic HCV infection[J]. Nat Rev Gastroenterol Hepatol, 2018, 15(5): 283-290. DOI: 10.1038/nrgastro.2017.172.
[16]	OCCHIPINTI V, FARINA L, VIGANÕ M, et al. Concomitant therapy with direct-acting antivirals and chemoimmunotherapy in HCV-associated diffuse large B-cell lymphoma[J]. Dig Liver Dis, 2019, 51(5): 719-723. DOI: 10.1016/j.dld.2018.10.019.
[17]	DEFRANCESCO I, ZERBI C, RATTOTTI S, et al. HCV infection and non-Hodgkin lymphomas: an evolving story[J]. Clin Exp Med, 2020, 20(3): 321-328. DOI: 10.1007/s10238-020-00615-6.
[18]	SEHN LH, SALLES G. Diffuse large B-cell lymphoma[J]. N Engl J Med, 2021, 384(9): 842-858. DOI: 10.1056/NEJMra2027612.
[19]	WANG L, LI LR, YOUNG KH. New agents and regimens for diffuse large B cell lymphoma[J]. J Hematol Oncol, 2020, 13(1): 175. DOI: 10.1186/s13045-020-01011-z.